HGF Overview
Molecule Name
Hepatocyte growth factor
Synonyms
HGF,HPTA,SF
Drug Development Progress
Drugs in Clinical Trials7
Approved Drugs1
Highest Development StageApproved
Target Synonym
EC 3.4.21.7，Hepatocyte Growth Factor (Hepapoietin A; Scatter Factor)，EC 3.4.21，HGF，Hepatopoietin-A，Scatter factor，Hepatocyte Growth Factor (Hepapoietin A，Scatter Factor)，Fibroblast-Derived Tumor Cytotoxic Factor，Lung Fibroblast-Derived Mitogen，SF，Deafness， Autosomal Recessive 39，Hepatopoietin A，DFNB39，F-TCF，HGFB，Hepatocyte Growth Factor，HPTA
Background
Hepatocyte growth factor (HGF) is a paracrine cellular growth, motility and morphogenic factor. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization. Hepatocyte growth factor is secreted by mesenchymal cells and acts as a multi-functional cytokine on cells of mainly epithelial origin. Its ability to stimulate mitogenesis, cell motility, and matrix invasion gives it a central role in angiogenesis, tumorogenesis, and tissue regeneration. In addition, HGF has been implicated in a variety of cancers, including of the lungs, pancreas, thyroid, colon, and breast.
HGF Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Fosgonimeton | NDX-1017; ATH-1017; ATH 1017 | Phase 3 Clinical | M3 Biotechnology | Alzheimer Disease; Dementia; Lewy Body Disease; Parkinson Disease | Details |
| RGL-2102 | RGL-2102; RGL2102 | Phase 3 Clinical | Shanghai Regenelead Therapies Co Ltd | Diabetic Foot; Ischemia; Ulcer; Wound Infection | Details |
| Ficlatuzumab | AV-299; SCH-900105 | Phase 3 Clinical | Aveo | Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cholangiocarcinoma; Colonic Neoplasms; Glioblastoma; Head and Neck Neoplasms; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Lymphoma; Multiple Myeloma; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Respiratory Tract Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Umikibart | YYB-101; NOV-1105; CLM-101 | Phase 2 Clinical | YooYoung Pharmaceutical Co Ltd | Colorectal Neoplasms; Solid tumours | Details |
| ATH-1020 | ATH-1020 | Phase 1 Clinical | Athira Pharma Inc | Nerve Degeneration | Details |
| ATH-1105 | ATH-1105 | Phase 1 Clinical | Athira Pharma Inc | Amyotrophic Lateral Sclerosis; Frontotemporal Dementia | Details |
| Microbiome-optimized autologous stem cell therapy (Biotech Holdings) | Clinical | Biotech Holdings | Peripheral Vascular Diseases | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Beperminogene perplasmid | AMG-0001-01; AMG-0001; DS-992; TREAT-HGF | Approved | Anges Mg, Osaka University | Collategene | Japan | Peripheral Arterial Disease; Ischemia | Anges Inc, null | 2019-03-01 | Arterial Occlusive Diseases; Atherosclerosis; Foot Ulcer; Ischemia; Peripheral Arterial Disease; Peripheral Vascular Diseases; Ulcer; Vascular Diseases | Details |